Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update

Thomas H Brannagan, Teresa Coelho, Annabel K Wang, Michael J Polydefkis, Peter J Dyck, John L Berk, Brian Drachman, Peter Gorevic, Carol Whelan, Isabel Conceição, Violaine Plante-Bordeneuve, Giampaolo Merlini, Laura Obici, Josep Maria Campistol Plana, Josep Gamez, Arnt V Kristen, Anna Mazzeo, Luca Gentile, Arvind Narayana, Kemi Olugemo, Peter Aquino, Merrill D Benson, Morie Gertz, NEURO-T. T. R. Open-Label Extension Investigators, Thomas H Brannagan, Teresa Coelho, Annabel K Wang, Michael J Polydefkis, Peter J Dyck, John L Berk, Brian Drachman, Peter Gorevic, Carol Whelan, Isabel Conceição, Violaine Plante-Bordeneuve, Giampaolo Merlini, Laura Obici, Josep Maria Campistol Plana, Josep Gamez, Arnt V Kristen, Anna Mazzeo, Luca Gentile, Arvind Narayana, Kemi Olugemo, Peter Aquino, Merrill D Benson, Morie Gertz, NEURO-T. T. R. Open-Label Extension Investigators

Abstract

Background: Hereditary transthyretin amyloidosis (hATTR/ATTRv) results from the deposition of misfolded transthyretin (TTR) throughout the body, including peripheral nerves. Inotersen, an antisense oligonucleotide inhibitor of hepatic TTR production, demonstrated a favorable efficacy and safety profile in patients with the polyneuropathy associated with hATTR in the NEURO-TTR (NCT01737398) study. We report longer-term efficacy and safety data for inotersen, with a median treatment exposure of 3 years.

Methods: Patients who satisfactorily completed NEURO-TTR were enrolled in its open-label extension (OLE) study. Efficacy assessments included the modified Neuropathy Impairment Score + 7 (mNIS + 7), Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) questionnaire total score, and the Short Form 36 (SF-36v2) Health Survey Physical Component Summary score. Safety and tolerability were also assessed. Efficacy is reported for patients living in Europe and North America (this cohort completed the study approximately 9 months before the remaining group of patients outside these regions); safety is reported for the full safety dataset, comprising patients living in Europe, North America, and Latin America/Australasia. This study is registered with ClinicalTrials.gov, identifier NCT02175004.

Results: In the Europe and North America cohort of the NEURO-TTR study, 113/141 patients (80.1%) completed the study, and 109 patients participated in the OLE study. A total of 70 patients continued to receive inotersen (inotersen-inotersen) and 39 switched from placebo to inotersen (placebo-inotersen). The placebo-inotersen group demonstrated sustained improvement in neurological disease progression as measured by mNIS + 7, compared with predicted worsening based on projection of the NEURO-TTR placebo data (estimated natural history). The inotersen-inotersen group demonstrated sustained benefit, as measured by mNIS + 7, Norfolk QoL-DN, and SF-36v2, compared with estimated natural history as well as compared with the placebo-inotersen group. With a maximum exposure of 6.2 years, inotersen was not associated with any additional safety concerns or increased toxicity in the OLE study. Platelet and renal monitoring were effective in reducing the risk of severe adverse events in the OLE study.

Conclusion: Inotersen treatment for > 3 years slowed progression of the polyneuropathy associated with hATTR, and no new safety signals were observed.

Keywords: Clinical trial; Familial amyloid polyneuropathy; Hereditary transthyretin amyloidosis; Inotersen; Peripheral neuropathies; Polyneuropathy.

Conflict of interest statement

TB reports being an advisory board member for Akcea Therapeutics, Pfizer, and Alnylam Pharmaceuticals; study investigator for Ionis Pharmaceuticals, Inc., and Alnylam Pharmaceuticals; and speaker for Alnylam Pharmaceuticals; and receiving honoraria for speaking for Akcea Therapeutics. TC reports receiving financial support to attend scientific meetings from Pfizer, Alnylam, Ionis, Akcea, and Biogen. AKW reports being study investigator, consultant, and speaker for Ionis Pharmaceuticals, Inc.; consultant for Pfizer; and study investigator for Alnylam. MJP reports receiving honoraria from Pfizer and Alnylam Pharmaceuticals, Inc. PJD reports receiving training and consulting honoraria from Ionis Pharmaceuticals, Inc., and Alnylam Pharmaceuticals. JLB reports receiving honoraria from Ionis Pharmaceuticals, Inc., and Alnylam Pharmaceuticals; and being a study investigator for Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Eidos BridgeBio, and Pfizer. BD reports being a consultant/advisory board member for Eidos and Alnylam Pharmaceuticals. PG declares no competing interests. CW reports being an advisory board member for Alnylam and Akcea Therapeutics. IC reports being a consultant for Alnylam and Pfizer; receiving honoraria for Alnylam, Pfizer, and Sanofi; and being on speaker bureaus for Alnylam, Pfizer, and Sanofi. VP-B reports receiving consulting honoraria for Alnylam Pharmaceuticals, Ionis, and Pfizer and travel honoraria from Ionis. GM declares no competing interests. LO reports receiving speaker honoraria from Akcea Therapeutics, Alnylam Pharmaceuticals, SOBI, and Pfizer. JMCP declares no competing interests. JG declares no competing interests. AVK reports receiving honoraria and fees for lectures and speakers bureaus from Alnylam Pharmaceuticals, Akcea Therapeutics, and Pfizer Inc. AM reports receiving speaker fees and consulting honoraria from Alnylam Pharmaceuticals, Akcea Therapeutics, and Pfizer Inc. LG reports receiving speaker fees and consulting honoraria from Pfizer. AN is a former employee of Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. KO is a former employee of Ionis Pharmaceuticals, Inc. PA is a former employee of Ionis Pharmaceuticals, Inc./Akcea Therapeutics. MDB reports being study investigator for Ionis Pharmaceuticals, Inc. MG reports receiving consulting honoraria from Ionis, AbbVie, Alnylam, Amgen, Annexon, Appellis, Celgene, Janssen, Medscape, Physicians Education Resource, Prothena, Research to Practice, Teva, and Spectrum, and grants from Spectrum.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
OLE median serum transthyretin (TTR) levels relative to NEURO-TTR baseline. The OLE baseline on the graph is noted as occurring 4 weeks after the end of the NEURO-TTR study because the maximum screening period in the OLE study was  generally 4 weeks. OLE open-label extension, SE standard error, TTR transthyretin
Fig. 2
Fig. 2
Mean change from NEURO-TTR baseline to OLE week 156 in efficacy measures. Mean (± SE) change from NEURO-TTR baseline in A the Modified Neuropathy Impairment Score + 7 (mNIS + 7); B the Norfolk Quality of Life–Diabetic Neuropathy Questionnaire Total Score (QoL-DN); C the 36-Item Short-Form Health Survey, version 2 (SF-36), Physical Component Summary score (PCS). The vertical dashed line represents OLE baseline (OLE week 0). Sample sizes for each time point and treatment group are indicated under the figure. The OLE baseline values were carried forward from the week 65 visit of the NEURO-TTR study for the SF-36 and from the week 66 visit for mNIS + 7 and QoL-DN measures. The OLE baseline on the graph is noted as occurring 4 weeks after the end of the NEURO-TTR study because the maximum screening period in the OLE study was generally 4 weeks. OLE, open-label extension, SE, standard error
Fig. 3
Fig. 3
Responder analyses for the NEURO-TTR Europe and North America cohort. Data are presented for A the Modified Neuropathy Impairment Score + 7 Neurophysiological Tests Composite Score (mNIS + 7), B the Norfolk Quality of Life–Diabetic Neuropathy Questionnaire Total Score (QoL-DN), and C the 36-Item Short-Form Health Survey, version 2 (SF-36), Physical Component Summary score (PCS). A patient was classified as a responder at various time points through week 156 if they showed no clinically meaningful progression based on the applicable threshold and had a recorded measurement at baseline and at the relevant time point. The OLE baseline on the graph is noted as occurring 4 weeks after the end of the NEURO-TTR study because the maximum screening period in the OLE study was generally 4 weeks. A For the inotersen–inotersen group, responders at all visits are based on change < 12.2 points from NEURO-TTR baseline. For the placebo–inotersen group, responders at NEURO-TTR week 35 and week 66 visits and OLE baseline visits are based on change < 12.2 points from NEURO-TTR baseline, while responders at all post-baseline OLE visits are based on change < 12.2 points from OLE baseline. B For the inotersen–inotersen group, responders at all visits are based on change < 8.8 points from NEURO-TTR baseline. For the placebo–inotersen group, responders at NEURO-TTR week 35 and week 66 visits and OLE baseline visits are based on change < 8.8 points from NEURO-TTR baseline, while responders at all post-baseline OLE visits are based on change < 8.8 points from OLE baseline. C For the inotersen–inotersen group, responders at all visits are based on change > –5 points from NEURO-TTR baseline. For the placebo–inotersen group, responders at NEURO-TTR week 35 and week 66 visits and OLE baseline visits are based on change > –5 points from NEURO-TTR baseline, while responders at all post-baseline OLE visits are based on change > –5 points from OLE baseline. OLE, open-label extension, RD, responder definition

References

    1. Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2020 doi: 10.1007/s10072-020-04889-2.
    1. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086–1097. doi: 10.1016/S1474-4422(11)70246-0.
    1. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G. Diagnosis, rognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–2466. doi: 10.1016/j.jacc.2015.09.075.
    1. Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23:S107–S112102.
    1. Coelho T, Maurer MS, Suhr OB. THAOS—The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63–76. doi: 10.1185/03007995.2012.754348.
    1. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C, Investigators THAOS. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey) J Am Coll Cardiol. 2016;68(2):161–172. doi: 10.1016/j.jacc.2016.03.596.
    1. Sekijima Y (2001) Hereditary transthyretin amyloidosis synonyms: familial amyloid polyneuropathy, familial transthyretin amyloidosis, hereditary ATTR amyloidosis. In: Adam MP, Ardinger HH, Pagon RA, et al (eds) Gene reviews. Seattle, WA: University of Washington. . (Accessed 14 Mar 2022)
    1. Gertz MA, Mauermann ML, Grogan M, Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: a review. Brain Behav. 2019;9(9):e01371. doi: 10.1002/brb3.1371.
    1. Dyck PJ, Lambert EH. Dissociated sensation in amyloidosis. Compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. Arch Neurol. 1969;20(5):490–507. doi: 10.1001/archneur.1969.00480110054005.
    1. Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109–2122. doi: 10.1007/s00415-019-09688-0.
    1. Inês M, Coelho T, Conceição I, Ferreira L, de Carvalho M, Costa J. Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study. Orphanet J Rare Dis. 2020;15(1):67. doi: 10.1186/s13023-020-1340-x.
    1. Lane T, Bangova A, Fontana M, Hutt DF, Strehina SG, Whelan CJ, Hawkins PN, Gillmore JD. Quality of life in ATTR amyloidosis. Orphanet J Rare Dis. 2015;10(Suppl 1):O26. doi: 10.1186/1750-1172-10-S1-O26.
    1. Stewart M, Shaffer S, Murphy B, Loftus J, Alvir J, Cicchetti M, Lenderking WR. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7(2):349–364. doi: 10.1007/s40120-018-0106-z.
    1. Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB, THAOS investigators THAOS: gastrointestinal manifestations of transthyretin amyloidosis—common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61. doi: 10.1186/1750-1172-9-61.
    1. Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR. Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2017;55(3):323–332. doi: 10.1002/mus.25257.
    1. Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T, European Network for TTR-FAP (ATTReuNET) First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14–S26. doi: 10.1097/WCO.0000000000000289.
    1. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH, 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. doi: 10.1056/NEJMoa1716793.
    1. Brannagan TH, Wang AK, Coelho T, Waddington Cruz M, Polydefkis MJ, Dyck PJ, Plante-Bordeneuve V, Berk JL, Barroso F, Merlini G, Conceição I, Hughes SG, Kwoh J, Jung SW, Guthrie S, Pollock M, Benson MD, Gertz M, NEURO-TTR open-label extension investigators Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol. 2020;27(8):1374–1381. doi: 10.1111/ene.14285.
    1. Yarlas A, Lovley A, Brown D, Kosinski M, Vera-Llonch M. Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study. J Neurol. 2022;269:323–335. doi: 10.1007/s00415-021-10635-1.
    1. Badhiwala JH, Witiw CD, Nassiri F, Akbar MA, Jaja B, Wilson JR, Fehlings MG. Minimum clinically important difference in SF-36 scores for use in degenerative cervical myelopathy. Spine (Phila Pa 1976) 2018;43(21):e1260–e1266. doi: 10.1097/BRS.0000000000002684.
    1. Ogura K, Yakoub MA, Christ AB, Fujiwara T, Nikolic Z, Boland P, Healey JH. What are the minimum clinically important differences in SF-36 scores in patients with orthopaedic oncologic conditions? Clin Orthop Relat Res. 2020;478(9):2148–2158. doi: 10.1097/CORR.0000000000001341.
    1. Auffinger B, Lam S, Shen J, Thaci B, Roitberg BZ. Usefulness of minimum clinically important difference for assessing patients with subaxial degenerative cervical spine disease: statistical versus substantial clinical benefit. Acta Neurochir (Wien) 2013;155(12):2345–2354. doi: 10.1007/s00701-013-1909-4.
    1. Lin X, Yarlas A, Vera-Llonch M, Baranwal N, Biber J, Brown D, Vogt B, Karam C. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. BMC Neurol. 2021;21(1):70. doi: 10.1186/s12883-021-02094-y.
    1. Yarlas A, Lovley A, McCausland K, Brown D, Vera-Llonch M, Conceição I, Karam C, Khella S, Obici L, Waddington-Cruz M. Early data on the long-term impact of inotersen on quality-of-life in patients with hereditary transthyretin amyloidosis polyneuropathy: open-label extension of NEURO-TTR. Neurol Ther. 2021;10(2):865–886. doi: 10.1007/s40120-021-00268-x.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera